FOLR1 and cancer: While the leap from in vitro cancer cell experimentation to clinical treatments is long and risky (e.g., Vintafolide), since the FRA has been established as being over-expressed on many cancers, Selenofolate would seem to offer a promising alternative option for treating TNBC and other FRA cancers.